Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying

Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer, outperforming historical controls. I view the ESMO-driven sell-off as overdone, given TNGX's strong cash position ($1B), FDA-aligned registrational design, and underappreciated dual-primary endpoint trial. Vopimetostat enables daraxonrasib dose-sparing, reducing toxicity and cost, making TNGX a preferred RAS combination partner with expanding partnership optionality.

Seeking Alpha • Oct 28, 2026

TNGX Stock Falls 16% Despite Positive Pancreatic Cancer Study Data

Tango Therapeutics stock falls 16.4% despite an 82% pancreatic cancer response rate and durable disease control, as investors weigh updated results and R&D cuts.

Zacks Investment Research • Oct 26, 2026

Tango Therapeutics Just Improved On This 'Unprecedented' Cancer Drug

Tango Therapeutics beat expectations Friday for its combination using Revolution Medicines' newly approved drug in pancreatic cancer.

Investors Business Daily • Oct 23, 2026

Tango Therapeutics Targets 2027 Phase III Trial After 82% Pancreatic Cancer Response Rate

Tango Therapeutics NASDAQ: TNGX said it plans to begin a global Phase III trial in the first half of 2027 evaluating vopimetostat in combination with daraxonrasib as a first-line treatment for patients with MTAP-deleted metastatic pancreatic ductal adenocarcinoma, or PDAC.

MarketBeat • Oct 23, 2026

Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data?

Tango Therapeutics Inc. (NASDAQ:TNGX) on Friday shared Phase 1/2 trial data for its investigational drug vopimetostat, revealing strong efficacy in treating advanced pancreatic and lung cancers.

Benzinga • Oct 23, 2026

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer Transcript

Seeking Alpha • Oct 23, 2026

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy

82% objective response rate, median progression-free survival (PFS) not yet reached, and 9-month PFS-rate of 88% in patients with 2L/3L pancreatic cancer treated with vopimetostat plus daraxonrasib

GlobeNewsWire • Oct 23, 2026

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET

GlobeNewsWire • Oct 16, 2026

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Sep 10, 2026

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.

GlobeNewsWire • Sep 3, 2026